Received for publication January 8, 2009.
Revised May 28, 2009.
Accepted for publication May 29, 2009.

Docking of 1,4-benzodiazepines in the ₁/₂ GABA_AR modulator site

Abstract

Positive allosteric modulation of the type-A -aminobutyric acid receptor (GABA_AR) via the benzodiazepine recognition site is the mechanism whereby diverse chemical classes of therapeutic agents act to reduce anxiety, induce and maintain sleep, reduce seizures, and induce conscious sedation. The binding of such therapeutic agents to this allosteric modulatory site increases the affinity of GABA for the agonist recognition site. A major unanswered question, however, relates to how positive allosteric modulators dock in the 1,4-benzodiazepine (BZD) recognition site. In the present study, the x-ray structure of an acetylcholine binding protein from the snail Lymnea Stagnalis and the results from site-directed affinity-labeling studies were used as the basis for modeling of the BZD binding pocket at the ₁/₂ subunit interface. A tethered BZD was introduced into the binding pocket, and molecular simulations were carried out to yield a set of candidate orientations of the BZD ligand in the binding pocket. Candidate orientations were refined based upon known structure-activity and stereospecificity characteristics of BZDs and the impact of the ₁H101R mutation. Results favor a model in which the BZD molecule is oriented such that the C5-phenyl substituent extends approximately parallel to the plane of the membrane, rather than parallel to the ion channel. Application of this computational modeling strategy, which integrates site-directed affinity labeling with structure-activity knowledge to create a molecular model of the docking of active ligands in the binding pocket, may provide a basis for the design of more selective GABA_AR modulators with enhanced therapeutic potential.

Key words: GABAA, GABAC, Molecular dynamics, Structure-activity relationships and modeling, Benzodiazepines